肺がん治療市場規模・予測（2020年～2030年）、世界・地域シェア、動向、成長機会分析レポート対象範囲治療タイプ別（非侵襲性、低侵襲性）、適応症別（非小細胞肺がん、小細胞肺がん）、エンドユーザー別（病院、腫瘍クリニック、研究センター、その他）、地域別（北米、欧州、アジア太平洋地域、中南米、中東・アフリカ地域）

Lung Cancer Therapy Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), End User (Hospitals, Oncology Clinics, Research Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)

肺がん治療市場は、2022年の310億1,800万米ドルから2030年には804億9,300万米ドルに成長すると予想され、2022年から2030年までの年平均成長率は12.7%を記録すると予測されている。個別化医療の一種である標的... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
The Insight Partners ザ・インサイトパートナーズ	2023年10月30日	US$4,550 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	206	英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

肺がん治療市場は、2022年の310億1,800万米ドルから2030年には804億9,300万米ドルに成長すると予想され、2022年から2030年までの年平均成長率は12.7%を記録すると予測されている。

個別化医療の一種である標的療法は、がん細胞を直接標的とするように設計された2種類以上の薬剤の組み合わせである。切除療法や化学療法などの治療法は、感染細胞とともに健康な細胞も破壊するため、患者全体の状態に影響を及ぼす可能性がある。標的療法は、がん細胞を選択的に死滅させ、健康な細胞の機能は妨げないように設計されている。最近の医療技術の発達に伴い、肺癌の治療に標的療法を用いることへの注目は著しく高まっている。科学者たちは、がん細胞の制御不能な増殖の原因となる肺がん細胞の突然変異の研究に注力している。2021年5月、米国食品医薬品局は成人非小細胞肺がん患者に対する初の治療薬であるルマクラス（ソトラシブ）を承認した。この治療法は、KRAS G12C変異を有し、少なくとも1回の前治療として全身療法を受けている患者に投与される。各社はEGFR、ALK、ROS1、KRASなどのバイオマーカーを利用して標的治療薬を開発しており、がん細胞内の変異のタイプを検出するのに役立っている。このように、企業が標的療法の開発に注力するようになっていることと、肺がん患者に対するその利点についての認識が高まっていることが相まって、肺がん治療市場に今後数年のうちに新たなトレンドがもたらされると予想される。

肺がん検診・治療に対する政府の取り組みが肺がん治療市場の成長を牽引

ジョンソン・エンド・ジョンソンが発表した記事によると、肺がんは世界におけるがん死亡の主な原因であり、一般的に後期に発見される。初期段階では、肺がん患者は目立った症状を示さないため、発見されたケースのほぼ50％において、がんはすでに転移段階に達している。このような肺がんの深刻な現状を受け、各国政府は早期発見、早期検診、早期治療への取り組みに力を入れている。

米国予防サービス専門委員会（USPSTF）によると、米国では、50～80歳の喫煙歴が年間20箱あり、現在喫煙しているか、過去15年以内に禁煙している人が肺癌を発症しやすい。したがって、米国予防サービス専門委員会（USPSTF）は、肺がんの早期発見を確実にするため、これらの人々に毎年低線量コンピュータ断層撮影法（LDCT）による肺がん検診を受けるよう推奨している。さらに2022年7月、米国のバイデン政権は、メディケアサービスの対象となる患者のがん治療を改善し、治療費を下げることを目的とした新しいモデルを導入した。

2021年7月、キャンサー・オーストラリアは保健高齢者医療省と提携し、オーストラリアにおける肺がん検診プログラムの実現可能性を評価した。実現可能性評価の結果が良好であったことから、2023年5月、オーストラリア政府保健・高齢者医療省は、全国肺がん検診プログラムの実施のため、2023年から2024年にかけて2億6380万米ドルを投資することを宣言した。このプログラムを通じて、保健・高齢者医療省は肺がんの予防と早期発見に重点を置いている。さらに、欧州保健連合（EU）が導入した「がん撲滅計画（Beating Cancer Plan）」は、肺がん患者の予防、治療、ケアに重点を置くことで、疾患の全経路に取り組むことを目的としている。

このように、肺がん患者の早期発見と適切な治療を目的とした政府による取り組みが急増していることが、肺がん治療市場の成長を後押ししている。

肺がん治療市場は、治療の種類、適応症、エンドユーザー、地域によって区分される。肺がん治療市場は、ワクチンタイプ別に非侵襲性と低侵襲性に二分される。低侵襲性セグメントはさらに、高周波アブレーション、マイクロ波アブレーション、熱アブレーション、冷凍アブレーション、化学アブレーション、光線力学的アブレーション、その他に分類される。肺がん治療市場は、適応症別に非小細胞肺がんと小細胞肺がんに区分される。エンドユーザー別では、病院、腫瘍クリニック、研究センター、その他に区分される。

地域別では、北米、欧州、アジア太平洋、中東・アフリカ、中南米に区分される。肺がん治療市場で最大の市場シェアを占めるのは北米である。北米が大きな市場シェアを占めているのは、喫煙の増加、タバコの消費、工業化による大気汚染の増加に起因する肺がん患者の増加によるものである。米国における肺がん治療市場の成長は、主に肺がん罹患率の増加、製品の上市、政府の取り組みによってもたらされている。肺がんは米国で2番目に多いがんである。米国癌協会（American Cancer Society, Inc.）によると、2023年現在、米国の成人〜238,340人（男性117,550人、女性120,790人）が肺癌と診断され、また〜127,070人（男性67,160人、女性59,910人）が肺癌が原因で死亡している。肺癌は癌による死亡の5人に1人を占め、米国における癌による死亡の主な原因となっている。同じ情報源によると、肺癌の診断の81％はNSCLCである。このように、同国における肺がん罹患率の増加は、米国の肺がん治療市場の成長を後押ししている。

企業による肺がん治療のためのさまざまな製品の発売も、市場の成長を後押ししている。例えば、2021年5月、米国FDAはルマクラス（ソトラシブ）を成人非小細胞肺がん患者に対する初の標的治療薬として承認した。これは、非小細胞肺がん（NSCLC）における変異の〜25％を報告するKRAS変異を有する腫瘍に対して承認された最初の標的療法である。さらに、2021年5月、米国FDAは、EGFRエクソン20挿入変異を有する局所進行性または転移性NSCLCの成人患者を対象に、上皮成長因子（EGF）およびMET受容体に対する二重特異性抗体であるamivantamab-vmjw（Rybrevant）を早期承認した。

2023年5月、デジタル戦略室が管理するホワイトハウスの公式ウェブサイトwhitehouse.govに掲載された報告書によると、地域がんセンター協会（ACCC）とアストラゼネカは、"アパラチア地方肺がん検診イニシアチブ "を通じて、アメリカの地方における肺がん検診を推進するために、個人を中心とした持続可能なアプローチを開発・実施するためのパートナーシップを締結した。アパラチア地域（ウェストバージニア州全域と他の12州の一部を含む）のがん死亡率は、米国の他の地域よりも10％高い。このイニシアチブは、肺がんの5年生存率を2倍にすることを目的としている。このような取り組みが、米国における肺がん治療市場の成長に寄与している。

ClinicalTrails.com、疾病対策予防センター（CDC）、食品医薬品局（FDA）、米国予防サービス作業部会（USPSTF）は、肺がん治療市場に関する報告書を作成する際に参照したいくつかの主要な一次情報源および二次情報源である。

ページTOPに戻る

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Lung Cancer Therapy Market, by Geography
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Lung Cancer Therapy Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. Lung Cancer Therapy Market - Key Industry Dynamics
5.1 Market Drivers:
5.1.1 Increase in Cases of Lung Cancer
5.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
5.2 Market Restraints
5.2.1 High Cost of Lung Cancer Therapy
5.3 Market Opportunities
5.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
5.4 Future Trends
5.4.1 Growing Demand for Targeted Therapy
5.5 Impact Analysis:
6. Lung Cancer Therapy Market - Global Market Analysis
6.1 Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
7. Global Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Therapy Type
7.1 Overview
7.2 Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
7.3 Non-Invasive Therapy
7.3.1 Overview
7.3.2 Non-Invasive Therapy: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Minimally Invasive
7.4.1 Overview
7.4.2 Minimally Invasive: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 Global: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
8. Global Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Indication
8.1 Overview
8.2 Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Non-Small Cell Lung Cancer
8.3.1 Overview
8.3.2 Non-Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Small Cell Lung Cancer
8.4.1 Overview
8.4.2 Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. Global Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Oncology Clinics
9.4.1 Overview
9.4.2 Oncology Clinics: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Research Centers
9.5.1 Overview
9.5.2 Research Centers: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
10. Lung Cancer Therapy Market - Geographical Analysis
10.1 North America Lung Cancer Therapy Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.3 North America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.3.1 North America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.4 North America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5 North America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6 North America Lung Cancer Therapy Market, by Country
10.1.6.1 US
10.1.6.1.1 Overview
10.1.6.1.2 US Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.1.3 US: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.1.3.1 US: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.1.4 US: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.1.5 US: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6.2 Canada
10.1.6.2.1 Overview
10.1.6.2.2 Canada Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.2.3 Canada: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.2.3.1 Canada: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.2.4 Canada: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.2.5 Canada: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6.3 Mexico
10.1.6.3.1 Overview
10.1.6.3.2 Mexico Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.3.3 Mexico: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.3.3.1 Mexico: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.3.4 Mexico: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.3.5 Mexico: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2 Europe Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.2.1 Overview
10.2.2 Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.3 Europe: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.3.1 Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.4 Europe: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5 Europe: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6 Europe Lung Cancer Therapy Market, by Country
10.2.6.1 UK
10.2.6.1.1 Overview
10.2.6.1.2 UK Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.1.3 UK: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.1.3.1 UK: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.1.4 UK: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.1.5 UK: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.2 Germany
10.2.6.2.1 Overview
10.2.6.2.2 Germany Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.2.3 Germany: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.2.3.1 Germany: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.2.4 Germany: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.2.5 Germany: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.3 France
10.2.6.3.1 Overview
10.2.6.3.2 France Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.3.3 France: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.3.3.1 France: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.3.4 France: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.3.5 France: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.4 Italy
10.2.6.4.1 Overview
10.2.6.4.2 Italy Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.4.3 Italy: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.4.3.1 Italy: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.4.4 Italy: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.4.5 Italy: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.5 Spain
10.2.6.5.1 Overview
10.2.6.5.2 Spain Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.5.3 Spain: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.5.3.1 Spain: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.5.4 Spain: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.5.5 Spain: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.6 Russia
10.2.6.6.1 Overview
10.2.6.6.2 Russia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.6.3 Russia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.6.3.1 Russia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.6.4 Russia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.6.5 Russia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.7 Rest of Europe
10.2.6.7.1 Overview
10.2.6.7.2 Rest of Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.7.3 Rest of Europe: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.7.3.1 Rest of Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.7.4 Rest of Europe: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.7.5 Rest of Europe: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3 Asia Pacific Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.3.1 Overview
10.3.2 Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.3 Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.3.1 Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.4 Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5 Asia Pacific: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6 Asia Pacific Lung Cancer Therapy Market, by Country
10.3.6.1 China
10.3.6.1.1 Overview
10.3.6.1.2 China Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.1.3 China: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.1.3.1 China: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.1.4 China: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.1.5 China: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.2 Japan
10.3.6.2.1 Overview
10.3.6.2.2 Japan Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.2.3 Japan: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.2.3.1 Japan: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.2.4 Japan: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.2.5 Japan: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.3 India
10.3.6.3.1 Overview
10.3.6.3.2 India Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.3.3 India: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.3.3.1 India: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.3.4 India: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.3.5 India: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.4 Australia
10.3.6.4.1 Overview
10.3.6.4.2 Australia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.4.3 Australia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.4.3.1 Australia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.4.4 Australia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.4.5 Australia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.5 South Korea
10.3.6.5.1 Overview
10.3.6.5.2 South Korea Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.5.3 South Korea: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.5.3.1 South Korea: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.5.4 South Korea: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.5.5 South Korea: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6 Southeast Asia
10.3.6.6.1 Overview
10.3.6.6.2 Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.3 Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.3.1 Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.4 Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.5 Southeast Asia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.6 Singapore
10.3.6.6.6.1 Singapore Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.6.2 Singapore: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.6.2.1 Singapore: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.6.3 Singapore: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.6.4 Singapore: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.7 Malaysia
10.3.6.6.7.1 Malaysia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.7.2 Malaysia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.7.2.1 Malaysia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.7.3 Malaysia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.7.4 Malaysia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.8 Indonesia
10.3.6.6.8.1 Indonesia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.8.2 Indonesia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.8.2.1 Indonesia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.8.3 Indonesia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.8.4 Indonesia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.9 Vietnam
10.3.6.6.9.1 Vietnam Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.9.2 Vietnam: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.9.2.1 Vietnam: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.9.3 Vietnam: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.9.4 Vietnam: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.10 Cambodia
10.3.6.6.10.1 Cambodia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.10.2 Cambodia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.10.2.1 Cambodia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.10.3 Cambodia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.10.4 Cambodia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.11 Philippines
10.3.6.6.11.1 Philippines Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.11.2 Philippines: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.11.2.1 Philippines: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.11.3 Philippines: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.11.4 Philippines: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.12 Rest of Southeast Asia
10.3.6.6.12.1 Rest of Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.12.2 Rest of Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.12.2.1 Rest of Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.12.3 Rest of Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.12.4 Rest of Southeast Asia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.7 Rest of Asia Pacific
10.3.6.7.1 Overview
10.3.6.7.2 Rest of Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.7.3 Rest of Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.7.3.1 Rest of Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.7.4 Rest of Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.7.5 Rest of Asia Pacific: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4 Middle East & Africa Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.4.1 Overview
10.4.2 Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.3 Middle East & Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.3.1 Middle East & Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.4 Middle East & Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5 Middle East & Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.1 Middle East & Africa Lung Cancer Therapy Market, by Country
10.4.5.2 Saudi Arabia
10.4.5.2.1 Overview
10.4.5.2.2 Saudi Arabia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.2.3 Saudi Arabia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.2.3.1 Saudi Arabia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.2.4 Saudi Arabia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.2.5 Saudi Arabia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.3 South Africa
10.4.5.3.1 Overview
10.4.5.3.2 South Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.3.3 South Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.3.3.1 South Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.3.4 South Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.3.5 South Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.4 UAE
10.4.5.4.1 Overview
10.4.5.4.2 UAE Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.4.3 UAE: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.4.3.1 UAE: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.4.4 UAE: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.4.5 UAE: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.5 Rest of Middle East Africa
10.4.5.5.1 Overview
10.4.5.5.2 Rest of Middle East Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.5.3 Rest of Middle East Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.5.3.1 Rest of Middle East Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.5.4 Rest of Middle East Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.5.5 Rest of Middle East Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5 South & Central America Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.5.1 Overview
10.5.2 South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.3 South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.3.1 South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.4 South & Central America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.5 South & Central America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6 South & Central America Lung Cancer Therapy Market, by Country
10.5.6.1 Brazil
10.5.6.1.1 Overview
10.5.6.1.2 Brazil Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.1.3 Brazil: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.1.3.1 Brazil: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.1.4 Brazil: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.1.5 Brazil: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6.2 Argentina
10.5.6.2.1 Overview
10.5.6.2.2 Argentina Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.2.3 Argentina: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.2.3.1 Argentina: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.2.4 Argentina: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.2.5 Argentina: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6.3 Rest of South & Central America
10.5.6.3.1 Overview
10.5.6.3.2 Rest of South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.3.3 Rest of South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.3.3.1 Rest of South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.3.4 Rest of South & Central America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.3.5 Rest of South & Central America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
11. Lung Cancer Therapy Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies in Lung Cancer Therapy Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Medtronic Plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 RF Medical Co Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Johnson & Johnson
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Merck KGaA
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Sun Pharmaceutical Industries Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Bioventus Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Olympus Corp
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Meiji Seika Pharma Co Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Advanz Pharma Corp
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

ページTOPに戻る

Table of Contents

Summary

The lung cancer therapy market is expected to grow from US$ 31.018 billion in 2022 to US$ 80.493 billion by 2030; it is anticipated to record a CAGR of 12.7% from 2022 to 2030.

Targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly target the cancerous cells. Therapies such as ablation and chemotherapy destroy healthy cells along with infected cells, which can affect the overall patient condition. Targeted therapy is designed in a way to selectively kill cancerous cells, keeping the function of healthy cells unhampered. With recent developments in medical technologies, focus on the use of targeted therapy for the treatment of lung cancer is increasing notably. Scientists are focusing on studying lung cancer cell mutations that are responsible for driving the uncontrolled growth of cancerous cells. In May 2021, the US Food and Drug Administration approved Lumakras (sotorasib), the first treatment for adult non-small cell lung cancer patients. This therapy is given to patients who have KRAS G12C mutation and have received at least one prior systemic therapy. The companies are using biomarkers such as EGFR, ALK, ROS1, and KRAS to develop targeted therapies, which help detect the type of mutation in the cancerous cells. Thus, the increasing focus of companies on the development of targeted therapies, coupled with the growing awareness about their benefits to lung cancer patients, is expected to bring new trends in the lung cancer therapy market in the coming years.

Government Initiatives for Screening and Treatment of Lung Cancer drives the growth the Lung Cancer Therapy Market

According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer.

As per United States Preventive Services Task Force (USPSTF), people from the age range of 50–80 with a smoking history of 20 packs per year, either presently smoking or having quit within the last 15 years, are more susceptible to developing lung cancer in the US. Hence, the United States Preventive Services Task Force (USPSTF) recommends these people undergo low-dose computed tomography (LDCT) screening for lung cancer every year to ensure the early detection of lung cancer. In addition, in July 2022, the Biden Administration in the US introduced a new model that aims to improve cancer care and lower the treatment cost for patients who are covered under Medicare services.

In July 2021, Cancer Australia partnered with the Department of Health and Aged Care to evaluate the feasibility of a lung cancer screening program in Australia. After obtaining positive results of the feasibility assessment, in May 2023, the Department of Health and Aged Care, the Government of Australia, declared an investment of US$ 263.8 million for 2023–2024 for the implementation of the National Lung Cancer Screening Program across the country. Through this program, the Department of Health and Aged Care focuses on the prevention and early detection of lung cancer. Further, the Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients.

Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the lung cancer therapy market.

The lung cancer therapy market is divided on the basis of therapy type, indication, end user, and geography. The lung cancer therapy market, by vaccine type, is bifurcated into noninvasive and minimally invasive. The minimally invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. The lung cancer therapy market, by indication, is segmented into non-small cell lung cancer and small cell lung cancer. The market, by end user, is segmented into hospitals, oncology clinics, research centers, and others.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the lung cancer therapy market. North America accounts for a significant market share owing to the growing incidences of lung cancer cases due to increase in smoking, consumption of tobacco, and increase in air pollution due to industrialization. The growth of the lung cancer therapy market in the US is mainly driven by the increasing incidence of lung cancer cases, product launches, and government initiatives. Lung cancer is the second most common cancer in the US. As per the American Cancer Society, Inc., as of 2023, ~238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer; also, ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung cancer accounts for 1 in 5 of all cancer deaths, making it a leading cause of cancer death in the US. As per the same source, NSCLC accounts for 81% of all lung cancer diagnoses. Thus, the increasing incidence of lung cancer in the country fuels the growth of the US lung cancer therapy market.

Various product launches for the treatment of lung cancer by companies are also bolstering the market growth. For instance, in May 2021, the US FDA approved Lumakras (sotorasib) as the first targeted therapy for adult non-small cell lung cancer patients. This is the first targeted therapy that is approved for tumors with KRAS mutation, which reports ~25% of mutations in non-small cell lung cancer (NSCLC). Moreover, in May 2021, the US FDA granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic NSCLC that comprises EGFR exon 20 insertion mutations.

As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca entered into a partnership for the development and implementation of person-centered and sustainable approaches to drive lung cancer screening in rural America through “Rural Appalachian Lung Cancer Screening Initiative.” The cancer mortality rate in the Appalachian region, including all of West Virginia and a few parts of 12 other states, is 10% higher than that of the rest of the US. This initiative aims to double the five-year survival rate for lung cancer. Such initiatives are contributing to the growth of the lung cancer therapy market in the US.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and United States Preventive Services Task Force (USPSTF) are a few key primary and secondary sources referred to while preparing the report on the lung cancer therapy market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

The Insight Partners 社の最新刊レポート

本レポートと同じKEY WORD（america europe）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

The Insight Partners 社の最新刊レポート

本レポートと同じKEY WORD（america europe）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?